Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Soleno Therapeutics (SLNO) Common Equity (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Common Equity for 9 consecutive years, with $450.1 million as the latest value for Q4 2025.

For Q4 2025, Common Equity changed N/A year-over-year to $450.1 million; the TTM value through Dec 2025 reached $450.1 million, changed N/A, while the annual FY2025 figure was $450.1 million, N/A changed from the prior year.
Common Equity hit $450.1 million in Q4 2025 for Soleno Therapeutics, down from $494.8 million in the prior quarter.
Across five years, Common Equity topped out at $494.8 million in Q3 2025 and bottomed at $232.3 million in Q1 2025.